DK3618845T3 - Peptider til behandling af diabetes - Google Patents
Peptider til behandling af diabetes Download PDFInfo
- Publication number
- DK3618845T3 DK3618845T3 DK18721806.0T DK18721806T DK3618845T3 DK 3618845 T3 DK3618845 T3 DK 3618845T3 DK 18721806 T DK18721806 T DK 18721806T DK 3618845 T3 DK3618845 T3 DK 3618845T3
- Authority
- DK
- Denmark
- Prior art keywords
- diabetes
- peptides
- treatment
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17169500 | 2017-05-04 | ||
PCT/EP2018/061547 WO2018202870A1 (en) | 2017-05-04 | 2018-05-04 | Peptides for treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3618845T3 true DK3618845T3 (da) | 2021-04-19 |
Family
ID=58671461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18721806.0T DK3618845T3 (da) | 2017-05-04 | 2018-05-04 | Peptider til behandling af diabetes |
Country Status (17)
Country | Link |
---|---|
US (2) | US10815283B2 (da) |
EP (1) | EP3618845B1 (da) |
JP (2) | JP2020518556A (da) |
KR (1) | KR20200003369A (da) |
CN (1) | CN110545834B (da) |
AU (1) | AU2018262805B2 (da) |
BR (1) | BR112019021886A2 (da) |
CA (1) | CA3061935A1 (da) |
DK (1) | DK3618845T3 (da) |
EA (1) | EA201992562A1 (da) |
ES (1) | ES2857749T3 (da) |
IL (1) | IL270199B1 (da) |
MX (1) | MX2019013096A (da) |
PL (1) | PL3618845T3 (da) |
SG (1) | SG11201908513RA (da) |
WO (1) | WO2018202870A1 (da) |
ZA (1) | ZA201905891B (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022516400A (ja) * | 2018-11-07 | 2022-02-28 | フォリクム エービー | 糖尿病治療のためのペプチド断片 |
AU2020260720A1 (en) * | 2019-04-24 | 2021-11-04 | Follicum Ab | Topical formulation |
KR20230138832A (ko) * | 2022-03-24 | 2023-10-05 | (주)케어젠 | 항당뇨 활성을 갖는 펩타이드 복합체 및 이의 용도 |
WO2023218094A1 (en) * | 2022-05-13 | 2023-11-16 | Coegin Pharma Ab | Agents inducing vascularisation |
WO2023218095A1 (en) * | 2022-05-13 | 2023-11-16 | Coegin Pharma Ab | Agents for stimulating tissue regeneration |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008513A1 (en) * | 1994-09-16 | 1996-03-21 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same |
WO1999015904A1 (en) | 1997-09-26 | 1999-04-01 | University Of Washington | Methods and compositions for diagnosing renal pathologies |
US6551990B2 (en) | 1998-12-07 | 2003-04-22 | University Of Washington | Methods of inhibiting ectopic calcification |
EP1269196B1 (en) | 2000-03-23 | 2007-11-21 | Glaxo Group Limited | Method of screening for inhibitors of osteopontin |
WO2001096395A2 (en) | 2000-06-13 | 2001-12-20 | Children's Medical Center Corporation | Biosynthetic oncolytic molecules and uses therefor |
EP1389130B1 (en) | 2001-05-17 | 2012-05-02 | Merck Serono SA | Use of osteopontin for the treatment and/or prevention of neurologic diseases |
EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
WO2003100007A2 (en) | 2002-05-24 | 2003-12-04 | Schering-Plough Ltd. | Eta-1 gene and methods for use |
WO2004103403A1 (ja) * | 2003-05-23 | 2004-12-02 | Immuno-Biological Laboratories Co., Ltd. | 免疫担当細胞活性化阻害剤およびその用途 |
WO2008086449A2 (en) | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
WO2008107422A1 (en) | 2007-03-02 | 2008-09-12 | National University Of Ireland, Galway | Osteopontin for the prediction and treatment of cardiovascular diseases |
WO2008131094A1 (en) | 2007-04-17 | 2008-10-30 | Pfizer Inc. | Method for controlling glucose uptake and insulin sensitivity |
CN101293916A (zh) | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途 |
BRPI0818810A2 (pt) * | 2007-10-31 | 2014-10-29 | Medimmune Llc | Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável. |
CN101215324B (zh) * | 2007-12-26 | 2010-11-24 | 吉林大学 | 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用 |
WO2011058182A1 (en) * | 2009-11-13 | 2011-05-19 | National University Of Ireland, Galway | Osteopontin-conditioned medium for the treatment of vascular diseases |
GB2493540A (en) | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
CN104640989A (zh) | 2012-07-20 | 2015-05-20 | 阿拉食品公司 | 用于抑制或防止肿瘤生长的骨桥蛋白肽片段 |
GB201406989D0 (en) * | 2014-04-17 | 2014-06-04 | Follicum Ab | Novel treatments |
IL299516A (en) | 2016-05-06 | 2023-02-01 | Astrazeneca Ab | Oligonucleotides conjugated to the GLP-1 receptor ligand complex and their uses |
-
2018
- 2018-05-04 PL PL18721806T patent/PL3618845T3/pl unknown
- 2018-05-04 SG SG11201908513R patent/SG11201908513RA/en unknown
- 2018-05-04 AU AU2018262805A patent/AU2018262805B2/en active Active
- 2018-05-04 EA EA201992562A patent/EA201992562A1/ru unknown
- 2018-05-04 BR BR112019021886-6A patent/BR112019021886A2/pt unknown
- 2018-05-04 DK DK18721806.0T patent/DK3618845T3/da active
- 2018-05-04 ES ES18721806T patent/ES2857749T3/es active Active
- 2018-05-04 CA CA3061935A patent/CA3061935A1/en active Pending
- 2018-05-04 IL IL270199A patent/IL270199B1/en unknown
- 2018-05-04 WO PCT/EP2018/061547 patent/WO2018202870A1/en active Search and Examination
- 2018-05-04 KR KR1020197027946A patent/KR20200003369A/ko not_active Application Discontinuation
- 2018-05-04 MX MX2019013096A patent/MX2019013096A/es unknown
- 2018-05-04 CN CN201880026723.5A patent/CN110545834B/zh active Active
- 2018-05-04 EP EP18721806.0A patent/EP3618845B1/en active Active
- 2018-05-04 JP JP2019555219A patent/JP2020518556A/ja active Pending
-
2019
- 2019-09-06 ZA ZA2019/05891A patent/ZA201905891B/en unknown
- 2019-10-29 US US16/666,960 patent/US10815283B2/en active Active
-
2020
- 2020-09-16 US US17/022,526 patent/US20210009648A1/en not_active Abandoned
-
2023
- 2023-03-28 JP JP2023051477A patent/JP2023082076A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201992562A1 (ru) | 2020-07-01 |
BR112019021886A2 (pt) | 2020-06-02 |
CN110545834B (zh) | 2024-02-20 |
IL270199B1 (en) | 2024-03-01 |
EP3618845A1 (en) | 2020-03-11 |
CA3061935A1 (en) | 2018-11-08 |
US20210009648A1 (en) | 2021-01-14 |
MX2019013096A (es) | 2019-12-16 |
KR20200003369A (ko) | 2020-01-09 |
US10815283B2 (en) | 2020-10-27 |
ZA201905891B (en) | 2022-03-30 |
CN110545834A (zh) | 2019-12-06 |
AU2018262805B2 (en) | 2022-02-17 |
EP3618845B1 (en) | 2021-01-13 |
PL3618845T3 (pl) | 2021-08-02 |
AU2018262805A1 (en) | 2019-11-21 |
JP2023082076A (ja) | 2023-06-13 |
SG11201908513RA (en) | 2019-11-28 |
JP2020518556A (ja) | 2020-06-25 |
US20200095297A1 (en) | 2020-03-26 |
WO2018202870A1 (en) | 2018-11-08 |
ES2857749T3 (es) | 2021-09-29 |
IL270199A (en) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
DK3463248T3 (da) | Anordnnger til anvendelse af lægemiddelanordninger | |
DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
DK3386531T3 (da) | Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis | |
DK3618845T3 (da) | Peptider til behandling af diabetes | |
DK3258919T3 (da) | Næsepulverformulering til behandling af hypoglykæmi | |
DK3524255T3 (da) | Sammensætning til behandling af acne | |
DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
DK3585808T3 (da) | Modificerede serpiner til behandlingen af bradykinin formidlet sygdom | |
DK3373931T3 (da) | Heterocykliske forbindelser til behandling af sygdom | |
DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
DK3484475T3 (da) | 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom | |
DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme |